External beam radiotherapy is associated with a 10% survival advantage in women with deeply myoinvasive, high-grade endometrial cancer only, but women at lower risk of recurrence do not benefit.
Pembrolizumab has robust, durable clinical benefit in patients with heavily pretreated CCGC and was tolerated in the overall population,” researchers wrote.
Drs Ursula A. Matulonis and Eloise Chapman-Davis discuss overcoming health disparities in endometrial cancer and increasing clinical trial enrollment of Black women.
The OncoSignature multiplex immunofluorescence assay received breakthrough device designation from the FDA for identifying patients with endometrial cancer who may benefit from ACR-368 (prexasertib) ...
The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, ...
In the next in our series, GP Dr Roger Henderson debunks common myths about prostate cancer – and highlights some less ...
Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025 95 patients enrolled ...
Leerink Partnrs issued their Q3 2025 earnings estimates for Zentalis Pharmaceuticals in a report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback